|
1
|
Parsons DW, Jones S, Zhang X, et al: An
integrated genomic analysis of human glioblastoma multiforme.
Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Balss J, Meyer J, Mueller W, Korshunov A,
Hartmann C and von Deimling A: Analysis of the IDH1 codon 132
mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bleeker FE, Atai NA, Lamba S, et al: The
prognostic IDH1 (R132) mutation is associated with reduced NADP
(+)-dependent IDH activity in glioblastoma. Acta Neuropathol.
119:487–494. 2010.
|
|
4
|
Bujko M, Kober P, Matyja E, et al:
Prognostic value of IDH1 mutations identified with PCR-RFLP assay
in glioblastoma patients. Mol Diagn Ther. 14:163–169. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Capper D, Weissert S, Balss J, et al:
Characterization of R132H mutation-specific IDH1 antibody binding
in brain tumors. Brain Pathol. 20:245–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dang L, White DW, Gross S, et al:
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Carli E, Wang X and Puget S: IDH1 and
IDH2 mutations in gliomas. N Engl J Med. 360:2248author reply 2249.
2009.
|
|
8
|
Dubbink HJ, Taal W, van Marion R, et al:
IDH1 mutations in low-grade astrocytomas predict survival but not
response to temozolomide. Neurology. 73:1792–1795. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ducray F, Marie Y and Sanson M: IDH1 and
IDH2 mutations in gliomas. N Engl J Med. 360:248author reply 2249.
2009.
|
|
10
|
Ferroli P, Acerbi F and Finocchiaro G:
From standard treatment to personalized medicine: role of IDH1
mutations in low-grade glioma evolution and treatment. World
Neurosurg. 73:234–236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Frezza C, Tennant DA and Gottlieb E: IDH1
mutations in gliomas: when an enzyme loses its grip. Cancer Cell.
17:7–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gravendeel LA, Kloosterhof NK, Bralten LB,
et al: Segregation of non-p. R132H mutations in IDH1 in distinct
molecular subtypes of glioma. Hum Mutat. 31:E1186–E1199. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hartmann C, Meyer J, Balss J, et al: Type
and frequency of IDH1 and IDH2 mutations are related to astrocytic
and oligodendroglial differentiation and age: a study of 1,010
diffuse gliomas. Acta Neuropathol. 118:469–474. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayden JT, Fruhwald MC, Hasselblatt M,
Ellison DW, Bailey S and Clifford SC: Frequent IDH1 mutations in
supratentorial primitive neuroectodermal tumors (sPNET) of adults
but not children. Cell Cycle. 8:1806–1807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Horbinski C, Kelly L, Nikiforov YE, Durso
MB and Nikiforova MN: Detection of IDH1 and IDH2 mutations by
fluorescence melting curve analysis as a diagnostic tool for brain
biopsies. TJ Mol Diagn. 12:487–492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Horbinski C, Kofler J, Kelly LM, Murdoch
GH and Nikiforova MN: Diagnostic use of IDH1/2 mutation analysis in
routine clinical testing of formalin-fixed, paraffin-embedded
glioma tissues. J Neuropathol Exp Neurol. 68:1319–1325. 2009.
View Article : Google Scholar
|
|
17
|
Houillier C, Wang X, Kaloshi G, et al:
IDH1 or IDH2 mutations predict longer survival and response to
temozolomide in low-grade gliomas. Neurology. 75:1560–1566. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ichimura K, Pearson DM, Kocialkowski S, et
al: IDH1 mutations are present in the majority of common adult
gliomas but rare in primary glioblastomas. Neurooncology.
11:341–347. 2009.PubMed/NCBI
|
|
19
|
Kang MR, Kim MS, Oh JE, et al: Mutational
analysis of IDH1 codon 132 in glioblastomas and other common
cancers. Int J Cancer. 125:353–355. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Komotar RJ, Starke RM, Sisti MB and
Connolly ES: IDH1 and IDH2 mutations in gliomas and the associated
induction of hypoxia-inducible factor and production of
2-hydroxyglutarate. Neurosurgery. 66:N20–N21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Larsen CJ: Mutations of IDH1 and 2 genes:
a molecular diagnosis of low-grade gliomas. Bull Cancer.
96:641–642. 2009.(In French).
|
|
22
|
Nobusawa S, Watanabe T, Kleihues P and
Ohgaki H: IDH1 mutations as molecular signature and predictive
factor of secondary glioblastomas. Clin Cancer Res. 15:6002–6007.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sanson M, Marie Y, Paris S, et al:
Isocitrate dehydrogenase 1 codon 132 mutation is an important
prognostic biomarker in gliomas. J Clin Oncol. 27:4150–4154. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sonoda Y, Kumabe T, Nakamura T, et al:
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
Cancer Sci. 100:1996–1998. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uno M, Oba-Shinjo SM, Silva R, et al: IDH1
mutations in a Brazilian series of glioblastoma. Clinics (Sao
Paulo). 66:163–165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Van den Bent MJ, Dubbink HJ, Marie Y, et
al: IDH1 and IDH2 mutations are prognostic but not predictive for
outcome in anaplastic oligodendroglial tumors: a report of the
European Organization for Research and Treatment of Cancer Brain
Tumor Group. Clin Cancer Res. 16:1597–1604. 2010.PubMed/NCBI
|
|
27
|
Watanabe T, Nobusawa S, Kleihues P and
Ohgaki H: IDH1 mutations are early events in the development of
astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan H, Parsons DW, Jin G, et al: IDH1 and
IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao S, Lin Y, Xu W, et al: Glioma-derived
mutations in IDH1 dominantly inhibit IDH1 catalytic activity and
induce HIF-1alpha. Science. 324:261–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thol F, Weissinger EM, Krauter J, et al:
IDH1 mutations in patients with myelodysplastic syndromes are
associated with an unfavorable prognosis. Haematologica.
95:1668–1674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murugan AK, Bojdani E and Xing M:
Identification and functional characterization of isocitrate
dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys
Res Commun. 393:555–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oki K, Takita J, Hiwatari M, et al: IDH1
and IDH2 mutations are rare in pediatric myeloid malignancies.
Leukemia. 25:382–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schnittger S, Haferlach C, Ulke M,
Alpermann T, Kern W and Haferlach T: IDH1 mutations are detected in
6.6% of 1414 AML patients and are associated with intermediate risk
karyotype and unfavorable prognosis in adults younger than 60 years
and unmutated NPM1 status. Blood. 116:5486–5496. 2010.
|
|
34
|
Weller M, Felsberg J, Hartmann C, et al:
Molecular predictors of progression-free and overall survival in
patients with newly diagnosed glioblastoma: a prospective
translational study of the German Glioma Network. J Clin Oncol.
27:5743–5750. 2009. View Article : Google Scholar
|
|
35
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jeon YK, Park K, Park CK, Paek SH, Jung HW
and Park SH: Chromosome 1p and 19q status and p53 and p16
expression patterns as prognostic indicators of oligodendroglial
tumors: a clinicopathological study using fluorescence in situ
hybridization. Neuropathology. 27:10–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Park CK, Park SH, Lee SH, et al:
Methylation status of the MGMT gene promoter fails to predict the
clinical outcome of glioblastoma patients treated with ACNU plus
cisplatin. Neuropathology. 29:443–449. 2009. View Article : Google Scholar : PubMed/NCBI
|
